story of the week
Neoadjuvant Durvalumab With or Without Stereotactic Body Radiotherapy in Patients With Early-Stage NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology